个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Yang Yunpeng[a] ; Sun Jiya[b] ; Wang Zhehai[c] ; Fang Jian[d] ; Yu Qitao[e] ; Han Baohui[f] ; Cang Shundong[g] ; Chen Gongyan[h] ; Mei Xiaodong[i] ; Yang Zhixiong[j] ; Ma Rui[k] ; Bi Minghong[l] ; Ren Xiubao[m] ; Zhou Jianying[n] ; Li Baolan[o] ; Song Yong[p] ; Feng Jifeng[q] ; Li Juan[r] ; He Zhiyong[s] ; Zhou Rui[t] ; Li Weimin[u] ; Lu You[v] ; Zhou Hui[w] ; Wang Shuyan[w] ; Sun Luyao[w] ; Puig Oscar[x] ; Mancao Christoph[b] ; Peng Bo[b] ; Fang Wenfeng[a] ; Xu Wei[b] ; Zhang Li[a,*1] ;
机构： [a]Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China [b]New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, People’s Republic of China [c]Medical Oncology Department, Shandong Cancer Hospital, Jinan, People’s Republic of China [d]Department of Thoracic Oncology II, Peking University Cancer Hospital, Beijing, People’s Republic of China [e]Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning City, People’s Republic of China [f]Department of Respiration, Shanghai Chest Hospital, Shanghai, People’s Republic of China [g]Department of Oncology, The Henan Province Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China [h]Department of Respiration, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China [i]Department of Respiration, Anhui Provincial Hospital, Hefei, People’s Republic of China [j]Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, People’s Republic of China [k]Medical Oncology Department of Thoracic Cancer, Liaoning Cancer Hospital, Shenyang, People’s Republic of China [l]Department of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People’s Republic of China [m]Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China [n]Department of Respiratory Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China [o]Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, People’s Republic of China [p]Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, People’s Republic of China [q]Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, People’s Republic of China [r]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, People’s Republic of China [s]Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, People’s Republic of China [t]Department of Respiration, Xiangya Second Hospital, Changsha, People’s Republic of China [u]Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, People’s Republic of China [v]Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China [w]Medical Science and Strategy Oncology, Innovent Biologics, Inc., Suzhou, People’s Republic of China [x]Translational Medicine, Oncology Business Unit, Eli Lilly and Company, New York, New York
出处：
DOI： 10.1016/j.jtho.2021.07.015
ISSN：

关键词： Nonsquamous NSCLC Sintilimab RNA sequencing MHC class-II antigen presentation pathway Predictive biomarker

摘要：
Sintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in nonsquamous NSCLC in the ORIENT-11 study. Updated overall survival (OS) and PFS data and corresponding biomarker analyses are reported here.In this study, a total of 397 patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC were assigned to sintilimab plus chemotherapy combination treatment (combo) group or placebo plus chemotherapy treatment group. The patients were stratified by programmed death-ligand 1 (PD-L1) expression levels. Immune signature profiles from tumor RNA sequencing and PD-L1 immunohistochemistry were correlated with clinical outcome to identify predictive biomarkers.As of January 2021, with median follow-up of 22.9 months, median OS was significantly improved in the combo group compared with the placebo plus chemotherapy treatment group (not reached versus 16.8 mo; hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.45-0.79, p = 0.0003). High or medium immune cell infiltration was strongly associated with improved PFS in the combo group, in contrast to absent or low immune cell infiltration, which suggests that chemotherapy could not prime "immune deserts" to obtain benefit from programmed cell death protein-1 inhibition. In particular, high major histocompatibility complex (MHC) class II presentation pathway expression was significantly correlated with prolonged PFS (HR = 0.32, 95% CI: 0.19-0.54, p < 0.0001) and OS (HR = 0.36, 95% CI: 0.20-0.64, p = 0.0005) in the combo group. Importantly, patients with low or absent PD-L1 but high MHC class II expression could still benefit from the combo treatment. In contrast, MHC class I antigen presentation pathway was less relevant in this combination setting.The addition of sintilimab to chemotherapy resulted to significantly longer OS in nonsquamous NSCLC. Expression of MHC class II antigen presentation pathway could identify patients benefiting most from this combination.Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

基金：
The study was funded by Innovent Biologics, Inc., National Key Research and Development Program of the People’s Republic of China (grant numbers 2016YFC0905500, 2016YFC0905503), the Chinese National Natural Science Foundation Project (grant numbers 82072558 and 81772476), and Medical Scientific Research Foundation of Guangdong Province (grant number C2018062).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [a]Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构： [a]Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China [*1]Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng East Road, Guangzhou, Guangdong 510060, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Yang Yunpeng,Sun Jiya,Wang Zhehai,et al.Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(12):2109-2120.doi:10.1016/j.jtho.2021.07.015.
APA：
Yang Yunpeng,Sun Jiya,Wang Zhehai,Fang Jian,Yu Qitao...&Zhang Li.(2021).Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study..JOURNAL OF THORACIC ONCOLOGY,16,(12)
MLA：
Yang Yunpeng,et al."Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.".JOURNAL OF THORACIC ONCOLOGY 16..12(2021):2109-2120

相关文献

[1]Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study [2]Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11). [3]Genome-Wide Profiling of Long Noncoding RNA Expression Patterns in Women With Repeated Implantation Failure by RNA Sequencing. [4]MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) [5]Prediction of Potential Biomarkers in Early-Stage Nasopharyngeal Carcinoma Based on Platelet RNA Sequencing [6]Single-cell RNA sequencing uncovers a neuron-like macrophage subset associated with cancer pain [7]Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma [8]Embryonic liver developmental trajectory revealed by single-cell RNA sequencing in the Foxa2eGFP mouse. [9]Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. [10]Long noncoding RNA LINC00921 serves as a predictive biomarker for lung adenocarcinoma: An observational study

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号